United Therapeutics Corp (UTHR) Reports Q4 EPS of $0.79, Reaffirms FY12, FY13 Guidance
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $513.12 -1.51%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
United Therapeutics Corp (NASDAQ: UTHR) reported Q4 EPS of $0.79, $0.08 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $195.2 million versus the consensus estimate of $204.81 million.
United Therapeutics Corp reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics Corp (UTHR) click here.
United Therapeutics Corp reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics Corp (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- Advance Auto Parts (AAP) PT Lowered to $43 at Truist Securities
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
